Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)

This study has been terminated.
(Business reasons)
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01656434
First received: July 31, 2012
Last updated: March 12, 2015
Last verified: March 2015
  Purpose

The purpose of this study was to assess the contraceptive efficacy of a nomegestrol acetate + 17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active American women at risk for pregnancy. Vaginal bleeding patterns of women taking NOMAC-E2 were assessed and compared to those of women taking a norethisterone acetate + ethinyl estradiol (NETA-EE) COC. The safety of NOMAC-E2 was also assessed.

Participants were randomized to receive either NOMAC-E2 or NETA-EE in a 3:1 ratio. As of Amendment 1 (which increased the sample size of the NOMAC-E2 group), the randomization ratio was adapted accordingly for participants randomized after the sample size increase.


Condition Intervention Phase
Contraception
Drug: NOMAC-E2
Drug: NETA-EE
Other: Placebo
Drug: ethinylestradiol (EE)
Drug: ferrous fumarate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 Years

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of In-Treatment Pregnancies Per 100 Woman Years of Exposure (Pearl Index) [ Time Frame: Up to 1 year (13 cycles) ] [ Designated as safety issue: No ]
    Primary Efficacy Outcome measure for this study was contraceptive efficacy, or the prevention of in-treatment pregnancy. The total incidence of in-treatment pregnancies was expressed as the Pearl Index, which is defined as the number of in-treatment pregnancies per 100 woman-years of exposure.


Secondary Outcome Measures:
  • Percentage of Participants With an Occurrence of Breakthrough Bleeding/Spotting [ Time Frame: Up to 1 year (13 cycles) ] [ Designated as safety issue: No ]
    Participants kept e-diaries to record their vaginal bleeding events. They were asked to record, on a daily basis, whether they experienced vaginal bleeding, which included BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. (This is also known as "breakthough" bleeding.) Vaginal bleeding that required >=1 pad/tampon per day was classified as BLEEDING. Vaginal bleeding that did not require a pad/tampon per day was classified as SPOTTING.

  • Percentage of Participants With an Absence of Withdrawal Bleeding [ Time Frame: Up to 1 year (13 cycles) ] [ Designated as safety issue: No ]
    Participants kept e-diaries to record vaginal bleeding events. They were asked to record, on a daily basis, whether vaginal bleeding was present. Absence of withdrawal bleeding was defined as no bleeding/spotting during the expected bleeding period.

  • Percentage of Participants Who Experienced At Least One Adverse Event [ Time Frame: Up to 54 weeks ] [ Designated as safety issue: Yes ]
    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

  • Number of Participants Who Experience at Least One Venous or Arterial Thrombotic/Thromboembolic Event [ Time Frame: Up to 54 weeks ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Body Weight [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    Participants' body weights were measured in a consistent manner throughout the trial, using standardized equirpment. Last In-Treatment Measurement refers to a participant's end of trial visit, the timing of which differed among participants.


Enrollment: 3173
Study Start Date: November 2012
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NOMAC-E2
Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
Drug: NOMAC-E2
NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
Other Names:
  • MK-8175A
  • SCH 900121
  • Org 10486-0 (NOMAC)
  • Org 2317 (E2)
Other: Placebo
tablet
Active Comparator: NETA-EE
Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
Drug: NETA-EE
NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
Other Name: Lo Loestrin® Fe
Drug: ethinylestradiol (EE)
EE 10 μg tablet
Drug: ferrous fumarate
ferrous fumarate 75 mg tablet

Detailed Description:

This study was terminated early. The decision to terminate the study was based upon difficulties encountered with data collection (related to incomplete e-Diary entries) in concert with business considerations. The decision was not related to any new or unexpected safety or efficacy findings with NOMAC-E2. As a result of this early termination, none of the pre-specified efficacy endpoints were analyzed.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Sexually active woman, at risk for pregnancy and in need of contraception
  • Not planning to use other contraceptive methods (including barrier methods [e.g., condoms]) than the study drug, during the study
  • Willing to use a COC for 12 months (13 cycles)
  • Body mass index (BMI) of ≥18 and <38 kg/m^2
  • Good physical and mental health
  • Willing to complete an electronic diary on a daily basis for the duration of the study

Exclusion Criteria:

  • Current smoker and age of >35 years
  • Presence or history of either venous thromboembolic diseases (deep vein thrombosis [DVT], pulmonary embolism) or arterial thromboembolic diseases (myocardial infarction, stroke)
  • History of migraine with focal neurological symptoms
  • Diabetes mellitus with vascular involvement
  • Less than two weeks of full remobilization from prolonged immobilization, major surgery, any surgery to the legs, or major trauma
  • Severe hypertension
  • Severe abnormal lipoproteins in the blood
  • Pancreatic dysfunction
  • Presence of history of severe liver disease or liver tumors
  • Known or suspected sex steroid-influenced malignancies (e.g., of the genital organs or the breasts)
  • Undiagnosed vaginal bleeding
  • Known or suspected pregnancy
  • Current or history of abuse of alcohol or drugs (e.g., laxatives)
  • Abnormal cervical smear at screening
  • Prior to start of treatment, spontaneous menstruation has not occurred following a delivery or abortion
  • Breastfeeding or has been breastfeeding within 2 months prior to start of treatment
  • Use of any investigational drugs and/or participation in any other clinical trial within 2 months prior to start of treatment
  • Use of any of the following medications prior to or during the study may prohibit inclusion: sex hormones (other than pre- and post-treatment non-injectable contraceptives), injectable hormonal contraception, phenytoin, barbiturates, primidone, bosentan, carbamazepine, topiramate, felbamate, rifampicin, ritonavir, nevirapine, efavirenz, griseofulvin, herbal remedies containing Hypericum perforatum (e.g., St. John's wort)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01656434

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01656434     History of Changes
Other Study ID Numbers: P06448, MK-8175A-022, SCH 900121 P06448
Study First Received: July 31, 2012
Results First Received: February 9, 2015
Last Updated: March 12, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
Combined Oral Contraceptives

Additional relevant MeSH terms:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Ethinyl Estradiol
Ferrous fumarate
Contraceptive Agents, Female
Estrogens
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Trace Elements

ClinicalTrials.gov processed this record on June 30, 2015